Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Triple Negative Breast Neoplasms 16Carcinoma, Transitional Cell 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Urinary Bladder Neoplasms 11Melanoma 10Carcinoma, Hepatocellular 9Neoplasms 8Carcinoma, Renal Cell 8Uterine Cervical Neoplasms 6Neoplasm Metastasis 6Lung Neoplasms 6Colorectal Neoplasms 5Ovarian Neoplasms 4Lymphoma, Follicular 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Cholangiocarcinoma 3Brain Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Gallbladder Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

fludarabine 4Cyclophosphamide 4Interferon-gamma 2pembrolizumab 1interferon gamma-1b 1atezolizumab 1Trabectedin 1Radiation 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Liposarcoma, Myxoid × atezolizumab × Clear all
NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡